Sangamo Therapeutics, Inc. (SGMO)
|52 Week Range||0.29-3.76|
|1y Target Est||-|
|DCF Unlevered||SGMO DCF ->|
|DCF Levered||SGMO LDCF ->|
|Debt / Equity||25.92%||Neutral|
Upgrades & Downgrades
Latest SGMO news
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
26 October 2023
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
25 October 2023
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast.
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology...
24 October 2023
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Pre-Clinical Data Showcasing its Epigenetic Regulation for Neurology and CAR-Treg Research at ESGCT.
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
20 September 2023
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit.
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases
25 August 2023
Rare disease stocks have a difficult task. The rarer a disease is, the less public research goes into studying it.
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
8 August 2023
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.29 per share a year ago.
7 Sorry Pharma Stocks to Sell in April Before It's Too Late
16 April 2023
Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing ...
Sangamo: Hemophilia A Program With Pfizer Key To Success
23 March 2023
Final results from the phase 3 AFFINE trial using giroctocogene fitelparvovec for the treatment of patients with Hemophilia A are expected in the 1st half of 2024. If phase 3 trial is successful, Pfiz...
Best Penny Stocks To Buy? 3 To Watch With Targets Up To 400%
23 February 2023
Analysts like these penny stocks but is it time to buy or not? The post Best Penny Stocks To Buy?